Found 8 matching trials
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
EARLY_PHASE1The goal of this phase 0 proof-of concept study is to measure the therapeut...
Location
Division of Nuclear Medicine, University Hospital Basel
SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC
PHASE1This is an investigator-initiated, single-center clinical trial designed to...
Location
University Medical Center Groningen
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases
PHASE2This trial will evaluate treatment for patients with solid tumors with acti...
Location
Multiple Locations
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
PHASE1The goal of this monocentric, open-label, randomized-controlled, reader-bli...
Location
University Hospital Basel, Department of Radiology and Nuclear Medicine
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
PHASE1This research study is designed to evaluate a type of scan called Ga-68-DOT...
Location
Massachusetts general Hospital
DOTA-TOC in Metastasized Neuroendocrine Tumors
PHASE2The investigators aim to explore the efficacy of \[90Y-DOTA\]-TOC and \[177...
Location
University Hospital
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
EARLY_PHASE1This is a prospective, pilot, single center, open-label study in patients w...
Location
University of California, San Francisco
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
PHASE1Meningiomas are known to be the most frequent intracranial neoplasms and ac...
Location
University Hospital Basel, Department of Neurosurgery